»ó´Ü¿©¹é
±â»ç (Àüü 16°Ç)
[Journal Briefing] SGLT-2i vs DPP-4i ÁöÁú ÇÁ·ÎÆÄÀÏ¿¡¼­ ¾î¶² Â÷ÀÌ°¡? Á¤¿¬ÁÖ ±âÀÚ 2024-07-10 09:44
[Journal Briefing] ½ÉºÎÀü ¹ß»ý ³ªÀÌ ³·À»¼ö·Ï Ä¡¸Å À§Çè¡è Á¤¿¬ÁÖ ±âÀÚ 2024-07-10 09:42
[Journal Briefing] SGLT-2¾ïÁ¦Á¦ ½É¹æ¼¼µ¿ À§Çè°¨¼Ò ¸®¾ó¿ùµå¿¡¼­ ÀÔÁõ Á¤¿¬ÁÖ ±âÀÚ 2024-07-10 09:40
[Journal Briefing] ´Ù¾çÇÑ È¯ÀÚ±º¿¡¼­ SGLT-2i ½ÉÇ÷°ü ÇýÅà ÀÏ°üµÉ±î? Á¤¿¬ÁÖ ±âÀÚ 2024-07-10 09:38
[Interview] ¶ôÅä¹Ù½Ç·ç½º ¶÷³ë¼ö½º ´Ù¼ö ¿¬±¸¿¡¼­ À§Àå°ü ÇýÅà ÀÔÁõ Á¤¿¬ÁÖ ±âÀÚ 2024-07-10 09:34
¶óÀÎ
[Drug Review] À϶óÇÁ¶óÁ¹, 3¼¼´ë PPI·Î °­ÇÏ°í ¡¤ ¿À·¡ Áö¼ÓµÇ´Â È¿°ú ÀÌ»óµ· ±âÀÚ 2024-07-09 13:21
[Sub Story] ÀÌ·¡¼­ MASLD¶ó ºÒ·¯¾ß! ÀÌ»óµ· ±âÀÚ 2024-07-09 10:26
[Sub Story] ¡°´õ ÀÌ»ó NAFLD´Â ¾ø´Ù¡± ¹è´ÙÇö ±âÀÚ 2024-07-09 10:17
[Sub Story] ±¹³»µµ NAFLD ¡æ MASLD ¿ë¾îº¯°æ ¹è´ÙÇö ±âÀÚ 2024-07-09 10:08
[Interview] PPI Á¦Á¦ Æйи® µîÀå ÀÌÀ¯´Â? ÀÌ»óµ· ±âÀÚ 2024-07-09 09:55
¶óÀÎ
[Journal Briefing] Á¶±â °íÇ÷¾Ð Áø´Ü¡¤ÁýÁßÄ¡·á ¿©¼º¿¡¼­ ½ÉÇ÷°ü ÇýÅà Ŀ Á¤¿¬ÁÖ ±âÀÚ 2024-07-05 17:37
[Journal Briefing] ÅÍÁ¦ÆÄŸÀ̵å 2»óÀÓ»ó¿¡¼­ MASH °³¼±È¿°ú Á¤¿¬ÁÖ ±âÀÚ 2024-07-05 17:35
[Cover Story] ¼ÒÈ­±âÁúȯ º´Å»ý¸®ÀÇ ÀÌÇØ¿Í Ä¡·áÀü·«ÀÇ º¯È­ ÀÌ»óµ· ±âÀÚ 2024-07-05 17:26
[Interview] ±Ë¾çÄ¡·á¿¡ »ê¾ïÁ¦Á¦+Á¡¸·º¸È£Á¦ º´¿ë È®´ëÀû¿ë ±æ ÅÕ´Ù ÀÌ»óµ· ±âÀÚ 2024-07-05 13:40
[Conference Report] ESD À¯¹ß ±Ë¾çÄ¡·á¿¡ Å×°íÇÁ¶óÀÜ+·¹¹Ù¹ÌÇÇµå ½Ã³ÊÁö È¿°ú ÀÔÁõ Á¤¿¬ÁÖ ±âÀÚ 2024-07-05 13:29
¶óÀÎ
[Conference Report] ´ç´¢º´ ȯÀÚ Ç÷´ç¡¤ÄÝ·¹½ºÅ×·Ñ ¸ÂÃãÄ¡·á Æз¯´ÙÀÓ THE MOST 2024-06-12 18:29
Back to Top